Lipid Carriers for MRNA Delivery

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2023 Oct 6

PMID 37799378

Authors

Wanting Zhang

Yuxin Jiang

Yonglong He

Hamza Boucetta

Jun Wu

Zhongjian Chen

Wei He

Affiliations

Soon will be listed here.

Abstract

Messenger RNA (mRNA) is the template for protein biosynthesis and is emerging as an essential active molecule to combat various diseases, including viral infection and cancer. Especially, mRNA-based vaccines, as a new type of vaccine, have played a leading role in fighting against the current global pandemic of COVID-19. However, the inherent drawbacks, including large size, negative charge, and instability, hinder its use as a therapeutic agent. Lipid carriers are distinguishable and promising vehicles for mRNA delivery, owning the capacity to encapsulate and deliver negatively charged drugs to the targeted tissues and release cargoes at the desired time. Here, we first summarized the structure and properties of different lipid carriers, such as liposomes, liposome-like nanoparticles, solid lipid nanoparticles, lipid-polymer hybrid nanoparticles, nanoemulsions, exosomes and lipoprotein particles, and their applications in delivering mRNA. Then, the development of lipid-based formulations as vaccine delivery systems was discussed and highlighted. Recent advancements in the mRNA vaccine of COVID-19 were emphasized. Finally, we described our future vision and perspectives in this field.

Citing Articles

Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.

Leong K, Tham S, Poh C Virol J. 2025; 22(1):71.

PMID: 40075519 PMC: 11900334. DOI: 10.1186/s12985-025-02645-6.

mRNA lipid nanoparticle formulation, characterization and evaluation.

Ma Y, VanKeulen-Miller R, Fenton O Nat Protoc. 2025; .

PMID: 40069324 DOI: 10.1038/s41596-024-01134-4.

Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.

Xu L, Shao Z, Fang X, Xin Z, Zhao S, Zhang H Exploration (Beijing). 2025; 5(1):20230165.

PMID: 40040830 PMC: 11875455. DOI: 10.1002/EXP.20230165.

Developing mRNA Nanomedicines with Advanced Targeting Functions.

Wang J, Cai L, Li N, Luo Z, Ren H, Zhang B Nanomicro Lett. 2025; 17(1):155.

PMID: 39979495 PMC: 11842722. DOI: 10.1007/s40820-025-01665-9.

Advances in nucleic acid-based cancer vaccines.

Liao H, Liu S J Biomed Sci. 2025; 32(1):10.

PMID: 39833784 PMC: 11748563. DOI: 10.1186/s12929-024-01102-w.

References

Agier J, Zelechowska P, Kozlowska E, Brzezinska-Blaszczyk E . Expression of surface and intracellular Toll-like receptors by mature mast cells. Cent Eur J Immunol. 2017; 41(4):333-338. PMC: 5382879. DOI: 10.5114/ceji.2016.65131. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Mirchandani Y, Patravale V, S B . Solid lipid nanoparticles for hydrophilic drugs. J Control Release. 2021; 335:457-464. DOI: 10.1016/j.jconrel.2021.05.032. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Lokugamage M, Vanover D, Beyersdorf J, Hatit M, Rotolo L, Echeverri E . Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021; 5(9):1059-1068. PMC: 10197923. DOI: 10.1038/s41551-021-00786-x. View

Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X . A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020; 30(10):936-939. PMC: 7429369. DOI: 10.1038/s41422-020-00392-7. View

Beloqui A, Solinis M, Rodriguez-Gascon A, Almeida A, Preat V . Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2015; 12(1):143-61. DOI: 10.1016/j.nano.2015.09.004. View

Yamada Y, Sato Y, Nakamura T, Harashima H . Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control. J Control Release. 2022; 348:357-369. DOI: 10.1016/j.jconrel.2022.05.033. View

Shi C, Zhang M, Tong M, Yang L, Pang L, Chen L . miR-148a is Associated with Obesity and Modulates Adipocyte Differentiation of Mesenchymal Stem Cells through Wnt Signaling. Sci Rep. 2015; 5:9930. PMC: 4441322. DOI: 10.1038/srep09930. View

10.

Viana I, Roussel S, Defrene J, Lima E, Barabe F, Bertrand N . Innate and adaptive immune responses toward nanomedicines. Acta Pharm Sin B. 2021; 11(4):852-870. PMC: 7955583. DOI: 10.1016/j.apsb.2021.02.022. View

11.

Judge A, McClintock K, Phelps J, MacLachlan I . Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther. 2005; 13(2):328-37. DOI: 10.1016/j.ymthe.2005.09.014. View

12.

Gupta A, Eral H, Hatton T, Doyle P . Nanoemulsions: formation, properties and applications. Soft Matter. 2016; 12(11):2826-41. DOI: 10.1039/c5sm02958a. View

13.

Plotkin S, Wang D, Oualim A, Diamond D, Kotton C, Mossman S . The Status of Vaccine Development Against the Human Cytomegalovirus. J Infect Dis. 2020; 221(Suppl 1):S113-S122. PMC: 7057802. DOI: 10.1093/infdis/jiz447. View

14.

Barile L, Vassalli G . Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174:63-78. DOI: 10.1016/j.pharmthera.2017.02.020. View

15.

Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z . Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021; 11(4):941-960. PMC: 8105778. DOI: 10.1016/j.apsb.2020.12.018. View

16.

Hadinoto K, Sundaresan A, Cheow W . Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013; 85(3 Pt A):427-43. DOI: 10.1016/j.ejpb.2013.07.002. View

17.

Schult P, Roth H, Adams R, Mas C, Imbert L, Orlik C . microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. Nat Commun. 2018; 9(1):2613. PMC: 6031695. DOI: 10.1038/s41467-018-05053-3. View

18.

Hajj K, Ball R, Deluty S, Singh S, Strelkova D, Knapp C . Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH. Small. 2019; 15(6):e1805097. DOI: 10.1002/smll.201805097. View

19.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

20.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View